Telix Pharmaceuticals Limited Stock Today
| TLX Stock | 16.49 1.07 6.94% |
Performance23 of 100
| Odds Of DistressLess than 3
|
Telix Pharmaceuticals is trading at 16.49 as of the 30th of November 2024; that is 6.94 percent up since the beginning of the trading day. The stock's open price was 15.42. Telix Pharmaceuticals has a very small chance of experiencing financial distress in the next few years and had a solid performance during the last 90 days. Equity ratings for Telix Pharmaceuticals Limited are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of June 2024 and ending today, the 30th of November 2024. Click here to learn more.
IPO Date 14th of November 2024 | Category Healthcare |
Telix Pharmaceuticals is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 334.72 M outstanding shares of which 5.92 K shares are at this time shorted by investors with about 0.16 days to cover. More on Telix Pharmaceuticals Limited
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Telix Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Old Name | Talanx AG | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceutical Products, Biotechnology, Healthcare, WSE WIG INDEX, SPASX 300, Australia All Ordinaries, DAX Midcap, HDAX Performance, HDAX Price, SPASX All Australian, ASX Small Ordinaries, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Telix Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Telix Pharmaceuticals' financial leverage. It provides some insight into what part of Telix Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Telix Pharmaceuticals Limited (TLX) is traded on NASDAQ Exchange in USA. It is located in 55 Flemington Road, North Melbourne, VIC, Australia, 3051 and employs 10 people. Telix Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a total capitalization of 5.16 B. Telix Pharmaceuticals runs under Healthcare sector within Biotechnology industry. The entity has 334.72 M outstanding shares of which 5.92 K shares are at this time shorted by investors with about 0.16 days to cover.
Check Telix Pharmaceuticals Probability Of Bankruptcy
Telix Pharmaceuticals Historical Income Statement
Telix Stock Against Markets
Telix Pharmaceuticals Corporate Management
| Richard MBA | Chief Therapeutics | Profile | |
| BSc BSc | Chief Scientist | Profile | |
| Lena LLB | Group Counsel | Profile | |
| Andreas MD | Chief Advisor | Profile | |
| Darren Patti | Group Officer | Profile | |
| Craig Ulrick | Chief Officer | Profile |
Additional Tools for Telix Stock Analysis
When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.